Universal Beteiligungs und Servicegesellschaft mbH Acquires 70,021 Shares of Progyny, Inc. $PGNY

Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 92.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 145,647 shares of the company's stock after acquiring an additional 70,021 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.17% of Progyny worth $3,750,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Federated Hermes Inc. raised its position in Progyny by 147.3% during the third quarter. Federated Hermes Inc. now owns 1,375 shares of the company's stock valued at $30,000 after acquiring an additional 819 shares in the last quarter. Versant Capital Management Inc raised its position in Progyny by 61.8% during the third quarter. Versant Capital Management Inc now owns 2,340 shares of the company's stock valued at $50,000 after acquiring an additional 894 shares in the last quarter. Covestor Ltd raised its position in Progyny by 164.9% during the third quarter. Covestor Ltd now owns 2,609 shares of the company's stock valued at $56,000 after acquiring an additional 1,624 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in Progyny during the second quarter valued at approximately $77,000. Finally, Quarry LP raised its position in Progyny by 2,004.1% during the third quarter. Quarry LP now owns 3,598 shares of the company's stock valued at $77,000 after acquiring an additional 3,427 shares in the last quarter. Institutional investors own 94.93% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on PGNY. Canaccord Genuity Group cut their price objective on shares of Progyny from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Wednesday, March 11th. BTIG Research dropped their price target on shares of Progyny from $35.00 to $30.00 and set a "buy" rating on the stock in a research report on Thursday, March 5th. Jefferies Financial Group reissued a "buy" rating and issued a $30.00 price target on shares of Progyny in a research report on Friday, March 6th. Truist Financial dropped their price target on shares of Progyny from $34.00 to $28.00 and set a "buy" rating on the stock in a research report on Monday, March 2nd. Finally, Wall Street Zen raised shares of Progyny from a "hold" rating to a "buy" rating in a research report on Saturday, April 18th. Nine analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $27.91.

Progyny Stock Up 0.2%

NASDAQ:PGNY opened at $18.42 on Thursday. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $28.75. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of 28.34, a P/E/G ratio of 1.06 and a beta of 0.99. The company's 50 day moving average is $18.04 and its 200-day moving average is $21.72.

Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.48 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.10. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The company had revenue of $318.40 million for the quarter, compared to analyst estimates of $314.26 million. During the same quarter last year, the firm posted $0.42 earnings per share. The company's quarterly revenue was up 6.7% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Research analysts predict that Progyny, Inc. will post 1.12 EPS for the current fiscal year.

Insider Activity

In other news, EVP Allison Swartz sold 4,657 shares of the firm's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total value of $81,031.80. Following the sale, the executive vice president owned 89,879 shares in the company, valued at approximately $1,563,894.60. This trade represents a 4.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 7,455 shares of company stock valued at $129,515 in the last 90 days. Company insiders own 9.90% of the company's stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.

Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.